Tailoring Molecules for Protein Pockets: a Transformer-based Generative Solution for Structured-based Drug Design

• URL: http://arxiv.org/abs/2209.06158v1
• Date: Tue, 30 Aug 2022 09:32:39 GMT
• Title: Tailoring Molecules for Protein Pockets: a Transformer-based Generative Solution for Structured-based Drug Design
• Authors: Kehan Wu, Yingce Xia, Yang Fan, Pan Deng, Haiguang Liu, Lijun Wu, Shufang Xie, Tong Wang, Tao Qin and Tie-Yan Liu
• Abstract summary: De novo drug design based on the structure of a target protein can provide novel drug candidates. We present a generative solution named TamGent that can directly generate candidate drugs from scratch for a given target.
• Score: 133.1268990638971
• License: http://creativecommons.org/licenses/by-nc-nd/4.0/
• Abstract: Structure-based drug design is drawing growing attentions in computer-aided drug discovery. Compared with the virtual screening approach where a pre-defined library of compounds are computationally screened, de novo drug design based on the structure of a target protein can provide novel drug candidates. In this paper, we present a generative solution named TamGent (Target-aware molecule generator with Transformer) that can directly generate candidate drugs from scratch for a given target, overcoming the limits imposed by existing compound libraries. Following the Transformer framework (a state-of-the-art framework in deep learning), we design a variant of Transformer encoder to process 3D geometric information of targets and pre-train the Transformer decoder on 10 million compounds from PubChem for candidate drug generation. Systematical evaluation on candidate compounds generated for targets from DrugBank shows that both binding affinity and drugability are largely improved. TamGent outperforms previous baselines in terms of both effectiveness and efficiency. The method is further verified by generating candidate compounds for the SARS-CoV-2 main protease and the oncogenic mutant KRAS G12C. The results show that our method not only re-discovers previously verified drug molecules , but also generates novel molecules with better docking scores, expanding the compound pool and potentially leading to the discovery of novel drugs.

Related papers

• DrugGen: Advancing Drug Discovery with Large Language Models and Reinforcement Learning Feedback [0.0]
  DrugGen is an enhanced model based on the DrugGPT structure. It is fine-tuned on approved drug-target interactions and optimized with proximal policy optimization. By producing high-quality small molecules, DrugGen provides a high-performance medium for advancing pharmaceutical research and drug discovery.
  arXiv  Detail & Related papers  (2024-11-20T01:21:07Z)
• BatGPT-Chem: A Foundation Large Model For Retrosynthesis Prediction [65.93303145891628]
  BatGPT-Chem is a large language model with 15 billion parameters, tailored for enhanced retrosynthesis prediction. Our model captures a broad spectrum of chemical knowledge, enabling precise prediction of reaction conditions. This development empowers chemists to adeptly address novel compounds, potentially expediting the innovation cycle in drug manufacturing and materials science.
  arXiv  Detail & Related papers  (2024-08-19T05:17:40Z)
• De Novo Drug Design with Joint Transformers [9.339914898177186]
  De novo drug design requires simultaneously generating novel molecules outside of training data and predicting their target properties. We propose Joint Transformer that combines a Transformer decoder, Transformer encoder, and a predictor in a joint generative model with shared weights. We formulate a probabilistic black-box optimization algorithm that employs Joint Transformer to generate novel molecules with improved target properties.
  arXiv  Detail & Related papers  (2023-10-03T14:09:15Z)
• Target Specific De Novo Design of Drug Candidate Molecules with Graph Transformer-based Generative Adversarial Networks [0.0]
  We propose an end-to-end generative system, DrugGEN, for the de novo design of drug candidate molecules. The system is trained using a large dataset of drug-like compounds and target-specific bioactive molecules. Using the open-access DrugGEN, it is possible to easily train models for other druggable proteins.
  arXiv  Detail & Related papers  (2023-02-15T18:59:27Z)
• A Transformer-based Generative Model for De Novo Molecular Design [4.6782243206450325]
  We propose a Transformer-based deep model for de novo target-specific molecular design. The proposed method is capable of generating both drug-like compounds and target-specific compounds.
  arXiv  Detail & Related papers  (2022-10-17T05:03:35Z)
• Retrieval-based Controllable Molecule Generation [63.44583084888342]
  We propose a new retrieval-based framework for controllable molecule generation. We use a small set of molecules to steer the pre-trained generative model towards synthesizing molecules that satisfy the given design criteria. Our approach is agnostic to the choice of generative models and requires no task-specific fine-tuning.
  arXiv  Detail & Related papers  (2022-08-23T17:01:16Z)
• Improved Drug-target Interaction Prediction with Intermolecular Graph Transformer [98.8319016075089]
  We propose a novel approach to model intermolecular information with a three-way Transformer-based architecture. Intermolecular Graph Transformer (IGT) outperforms state-of-the-art approaches by 9.1% and 20.5% over the second best for binding activity and binding pose prediction respectively. IGT exhibits promising drug screening ability against SARS-CoV-2 by identifying 83.1% active drugs that have been validated by wet-lab experiments with near-native predicted binding poses.
  arXiv  Detail & Related papers  (2021-10-14T13:28:02Z)
• Pharmacoprint -- a combination of pharmacophore fingerprint and artificial intelligence as a tool for computer-aided drug design [6.053347262128918]
  We propose a high-resolution, pharmacophore fingerprint called Pharmacoprint. It encodes the presence, types, and relationships between pharmacophore features of a molecule.
  arXiv  Detail & Related papers  (2021-10-04T11:36:39Z)
• Learning To Navigate The Synthetically Accessible Chemical Space Using Reinforcement Learning [75.95376096628135]
  We propose a novel forward synthesis framework powered by reinforcement learning (RL) for de novo drug design. In this setup, the agent learns to navigate through the immense synthetically accessible chemical space. We describe how the end-to-end training in this study represents an important paradigm in radically expanding the synthesizable chemical space.
  arXiv  Detail & Related papers  (2020-04-26T21:40:03Z)
• CogMol: Target-Specific and Selective Drug Design for COVID-19 Using Deep Generative Models [74.58583689523999]
  We propose an end-to-end framework, named CogMol, for designing new drug-like small molecules targeting novel viral proteins. CogMol combines adaptive pre-training of a molecular SMILES Variational Autoencoder (VAE) and an efficient multi-attribute controlled sampling scheme. CogMol handles multi-constraint design of synthesizable, low-toxic, drug-like molecules with high target specificity and selectivity.
  arXiv  Detail & Related papers  (2020-04-02T18:17:20Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.